

Global Cancer Minimal Residual Disease Testing Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/G99B1D8E24D1EN.html>

Date: October 2024

Pages: 161

Price: US\$ 3,400.00 (Single User License)

ID: G99B1D8E24D1EN

Abstracts

Report Overview

Minimal residual disease (MRD) is a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.

The global Cancer Minimal Residual Disease Testing market size was estimated at USD 956.60 million in 2023 and is projected to reach USD 1758.67 million by 2032, exhibiting a CAGR of 7.00% during the forecast period.

North America Cancer Minimal Residual Disease Testing market size was estimated at USD 280.07 million in 2023, at a CAGR of 6.00% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Cancer Minimal Residual Disease Testing market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Cancer Minimal Residual Disease Testing Market, this report introduces in detail

the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Cancer Minimal Residual Disease Testing market in any manner.

Global Cancer Minimal Residual Disease Testing Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Adaptive Biotechnologies Corporation

ArcherDX

Inc. (Invitae Corporation)

Asuragen

Arup Laboratories

Bio-Rad Laboratories

Cergentis B.V.

F. Hoffmann- La Roche Ltd

Guardant Health

ICON plc

Invivoscribe

Laboratory Corporation of America Holdings

Mission Bio

Natera

Inc.

NeoGenomics Laboratories

Opko Health

Quest Diagnostics Incorporated

Sysmex Corporation

Genetron Health

Market Segmentation (by Type)

Flow Cytometry

Polymerase Chain Reaction (PCR)

Next-Generation Sequencing (NGS)

Other

Market Segmentation (by Application)

Hematological Malignancies

Leukemia

Lymphoma

Solid Tumors

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Cancer Minimal Residual Disease Testing Market

Overview of the regional outlook of the Cancer Minimal Residual Disease Testing Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Cancer Minimal Residual Disease Testing Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application,

covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Cancer Minimal Residual Disease Testing, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

- 1.1 Market Definition and Statistical Scope of Cancer Minimal Residual Disease Testing
- 1.2 Key Market Segments
 - 1.2.1 Cancer Minimal Residual Disease Testing Segment by Type
 - 1.2.2 Cancer Minimal Residual Disease Testing Segment by Application
- 1.3 Methodology & Sources of Information
 - 1.3.1 Research Methodology
 - 1.3.2 Research Process
 - 1.3.3 Market Breakdown and Data Triangulation
 - 1.3.4 Base Year
 - 1.3.5 Report Assumptions & Caveats

2 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW

- 2.1 Global Market Overview
 - 2.1.1 Global Cancer Minimal Residual Disease Testing Market Size (M USD) Estimates and Forecasts (2019-2032)
 - 2.1.2 Global Cancer Minimal Residual Disease Testing Sales Estimates and Forecasts (2019-2032)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

3 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET COMPETITIVE LANDSCAPE

- 3.1 Global Cancer Minimal Residual Disease Testing Sales by Manufacturers (2019-2024)
- 3.2 Global Cancer Minimal Residual Disease Testing Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Cancer Minimal Residual Disease Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Cancer Minimal Residual Disease Testing Average Price by Manufacturers (2019-2024)
- 3.5 Manufacturers Cancer Minimal Residual Disease Testing Sales Sites, Area Served, Product Type
- 3.6 Cancer Minimal Residual Disease Testing Market Competitive Situation and Trends

- 3.6.1 Cancer Minimal Residual Disease Testing Market Concentration Rate
- 3.6.2 Global 5 and 10 Largest Cancer Minimal Residual Disease Testing Players Market Share by Revenue
- 3.6.3 Mergers & Acquisitions, Expansion

4 CANCER MINIMAL RESIDUAL DISEASE TESTING INDUSTRY CHAIN ANALYSIS

- 4.1 Cancer Minimal Residual Disease Testing Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
 - 5.5.1 New Product Developments
 - 5.5.2 Mergers & Acquisitions
 - 5.5.3 Expansions
 - 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies

6 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Cancer Minimal Residual Disease Testing Sales Market Share by Type (2019-2024)
- 6.3 Global Cancer Minimal Residual Disease Testing Market Size Market Share by Type (2019-2024)
- 6.4 Global Cancer Minimal Residual Disease Testing Price by Type (2019-2024)

7 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Cancer Minimal Residual Disease Testing Market Sales by Application (2019-2024)
- 7.3 Global Cancer Minimal Residual Disease Testing Market Size (M USD) by Application (2019-2024)
- 7.4 Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2024)

8 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET CONSUMPTION BY REGION

- 8.1 Global Cancer Minimal Residual Disease Testing Sales by Region
 - 8.1.1 Global Cancer Minimal Residual Disease Testing Sales by Region
 - 8.1.2 Global Cancer Minimal Residual Disease Testing Sales Market Share by Region
- 8.2 North America
 - 8.2.1 North America Cancer Minimal Residual Disease Testing Sales by Country
 - 8.2.2 U.S.
 - 8.2.3 Canada
 - 8.2.4 Mexico
- 8.3 Europe
 - 8.3.1 Europe Cancer Minimal Residual Disease Testing Sales by Country
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 U.K.
 - 8.3.5 Italy
 - 8.3.6 Russia
- 8.4 Asia Pacific
 - 8.4.1 Asia Pacific Cancer Minimal Residual Disease Testing Sales by Region
 - 8.4.2 China
 - 8.4.3 Japan
 - 8.4.4 South Korea
 - 8.4.5 India
 - 8.4.6 Southeast Asia
- 8.5 South America
 - 8.5.1 South America Cancer Minimal Residual Disease Testing Sales by Country
 - 8.5.2 Brazil
 - 8.5.3 Argentina
 - 8.5.4 Columbia
- 8.6 Middle East and Africa

8.6.1 Middle East and Africa Cancer Minimal Residual Disease Testing Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET PRODUCTION BY REGION

9.1 Global Production of Cancer Minimal Residual Disease Testing by Region (2019-2024)

9.2 Global Cancer Minimal Residual Disease Testing Revenue Market Share by Region (2019-2024)

9.3 Global Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Cancer Minimal Residual Disease Testing Production

9.4.1 North America Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2024)

9.4.2 North America Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Cancer Minimal Residual Disease Testing Production

9.5.1 Europe Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2024)

9.5.2 Europe Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Cancer Minimal Residual Disease Testing Production (2019-2024)

9.6.1 Japan Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2024)

9.6.2 Japan Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Cancer Minimal Residual Disease Testing Production (2019-2024)

9.7.1 China Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2024)

9.7.2 China Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2024)

10 KEY COMPANIES PROFILE

10.1 Adaptive Biotechnologies Corporation

10.1.1 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Basic Information

10.1.2 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Overview

10.1.3 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Market Performance

10.1.4 Adaptive Biotechnologies Corporation Business Overview

10.1.5 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing SWOT Analysis

10.1.6 Adaptive Biotechnologies Corporation Recent Developments

10.2 ArcherDX

10.2.1 ArcherDX Cancer Minimal Residual Disease Testing Basic Information

10.2.2 ArcherDX Cancer Minimal Residual Disease Testing Product Overview

10.2.3 ArcherDX Cancer Minimal Residual Disease Testing Product Market Performance

10.2.4 ArcherDX Business Overview

10.2.5 ArcherDX Cancer Minimal Residual Disease Testing SWOT Analysis

10.2.6 ArcherDX Recent Developments

10.3 Inc. (Invitae Corporation)

10.3.1 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Basic Information

10.3.2 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Overview

10.3.3 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Market Performance

10.3.4 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing SWOT Analysis

10.3.5 Inc. (Invitae Corporation) Business Overview

10.3.6 Inc. (Invitae Corporation) Recent Developments

10.4 Asuragen

10.4.1 Asuragen Cancer Minimal Residual Disease Testing Basic Information

10.4.2 Asuragen Cancer Minimal Residual Disease Testing Product Overview

10.4.3 Asuragen Cancer Minimal Residual Disease Testing Product Market Performance

10.4.4 Asuragen Business Overview

10.4.5 Asuragen Recent Developments

10.5 Arup Laboratories

- 10.5.1 Arup Laboratories Cancer Minimal Residual Disease Testing Basic Information
- 10.5.2 Arup Laboratories Cancer Minimal Residual Disease Testing Product Overview
- 10.5.3 Arup Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
- 10.5.4 Arup Laboratories Business Overview
- 10.5.5 Arup Laboratories Recent Developments
- 10.6 Bio-Rad Laboratories
 - 10.6.1 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Basic Information
 - 10.6.2 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Overview
 - 10.6.3 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.6.4 Bio-Rad Laboratories Business Overview
 - 10.6.5 Bio-Rad Laboratories Recent Developments
- 10.7 Cergentis B.V.
 - 10.7.1 Cergentis B.V. Cancer Minimal Residual Disease Testing Basic Information
 - 10.7.2 Cergentis B.V. Cancer Minimal Residual Disease Testing Product Overview
 - 10.7.3 Cergentis B.V. Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.7.4 Cergentis B.V. Business Overview
 - 10.7.5 Cergentis B.V. Recent Developments
- 10.8 F. Hoffmann- La Roche Ltd
 - 10.8.1 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Basic Information
 - 10.8.2 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Overview
 - 10.8.3 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.8.4 F. Hoffmann- La Roche Ltd Business Overview
 - 10.8.5 F. Hoffmann- La Roche Ltd Recent Developments
- 10.9 Guardant Health
 - 10.9.1 Guardant Health Cancer Minimal Residual Disease Testing Basic Information
 - 10.9.2 Guardant Health Cancer Minimal Residual Disease Testing Product Overview
 - 10.9.3 Guardant Health Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.9.4 Guardant Health Business Overview
 - 10.9.5 Guardant Health Recent Developments
- 10.10 ICON plc

- 10.10.1 ICON plc Cancer Minimal Residual Disease Testing Basic Information
- 10.10.2 ICON plc Cancer Minimal Residual Disease Testing Product Overview
- 10.10.3 ICON plc Cancer Minimal Residual Disease Testing Product Market Performance
- 10.10.4 ICON plc Business Overview
- 10.10.5 ICON plc Recent Developments
- 10.11 Invivoscribe
 - 10.11.1 Invivoscribe Cancer Minimal Residual Disease Testing Basic Information
 - 10.11.2 Invivoscribe Cancer Minimal Residual Disease Testing Product Overview
 - 10.11.3 Invivoscribe Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.11.4 Invivoscribe Business Overview
 - 10.11.5 Invivoscribe Recent Developments
- 10.12 Laboratory Corporation of America Holdings
 - 10.12.1 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Basic Information
 - 10.12.2 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Overview
 - 10.12.3 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.12.4 Laboratory Corporation of America Holdings Business Overview
 - 10.12.5 Laboratory Corporation of America Holdings Recent Developments
- 10.13 Mission Bio
 - 10.13.1 Mission Bio Cancer Minimal Residual Disease Testing Basic Information
 - 10.13.2 Mission Bio Cancer Minimal Residual Disease Testing Product Overview
 - 10.13.3 Mission Bio Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.13.4 Mission Bio Business Overview
 - 10.13.5 Mission Bio Recent Developments
- 10.14 Natera
 - 10.14.1 Natera Cancer Minimal Residual Disease Testing Basic Information
 - 10.14.2 Natera Cancer Minimal Residual Disease Testing Product Overview
 - 10.14.3 Natera Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.14.4 Natera Business Overview
 - 10.14.5 Natera Recent Developments
- 10.15 Inc.
 - 10.15.1 Inc. Cancer Minimal Residual Disease Testing Basic Information
 - 10.15.2 Inc. Cancer Minimal Residual Disease Testing Product Overview

- 10.15.3 Inc. Cancer Minimal Residual Disease Testing Product Market Performance
- 10.15.4 Inc. Business Overview
- 10.15.5 Inc. Recent Developments
- 10.16 NeoGenomics Laboratories
 - 10.16.1 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Basic Information
 - 10.16.2 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Overview
 - 10.16.3 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.16.4 NeoGenomics Laboratories Business Overview
 - 10.16.5 NeoGenomics Laboratories Recent Developments
- 10.17 Opko Health
 - 10.17.1 Opko Health Cancer Minimal Residual Disease Testing Basic Information
 - 10.17.2 Opko Health Cancer Minimal Residual Disease Testing Product Overview
 - 10.17.3 Opko Health Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.17.4 Opko Health Business Overview
 - 10.17.5 Opko Health Recent Developments
- 10.18 Quest Diagnostics Incorporated
 - 10.18.1 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Basic Information
 - 10.18.2 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Overview
 - 10.18.3 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.18.4 Quest Diagnostics Incorporated Business Overview
 - 10.18.5 Quest Diagnostics Incorporated Recent Developments
- 10.19 Sysmex Corporation
 - 10.19.1 Sysmex Corporation Cancer Minimal Residual Disease Testing Basic Information
 - 10.19.2 Sysmex Corporation Cancer Minimal Residual Disease Testing Product Overview
 - 10.19.3 Sysmex Corporation Cancer Minimal Residual Disease Testing Product Market Performance
 - 10.19.4 Sysmex Corporation Business Overview
 - 10.19.5 Sysmex Corporation Recent Developments
- 10.20 Genetron Health
 - 10.20.1 Genetron Health Cancer Minimal Residual Disease Testing Basic Information

- 10.20.2 Genetron Health Cancer Minimal Residual Disease Testing Product Overview
- 10.20.3 Genetron Health Cancer Minimal Residual Disease Testing Product Market Performance
- 10.20.4 Genetron Health Business Overview
- 10.20.5 Genetron Health Recent Developments

11 CANCER MINIMAL RESIDUAL DISEASE TESTING MARKET FORECAST BY REGION

- 11.1 Global Cancer Minimal Residual Disease Testing Market Size Forecast
- 11.2 Global Cancer Minimal Residual Disease Testing Market Forecast by Region
 - 11.2.1 North America Market Size Forecast by Country
 - 11.2.2 Europe Cancer Minimal Residual Disease Testing Market Size Forecast by Country
 - 11.2.3 Asia Pacific Cancer Minimal Residual Disease Testing Market Size Forecast by Region
 - 11.2.4 South America Cancer Minimal Residual Disease Testing Market Size Forecast by Country
 - 11.2.5 Middle East and Africa Forecasted Consumption of Cancer Minimal Residual Disease Testing by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

- 12.1 Global Cancer Minimal Residual Disease Testing Market Forecast by Type (2025-2032)
 - 12.1.1 Global Forecasted Sales of Cancer Minimal Residual Disease Testing by Type (2025-2032)
 - 12.1.2 Global Cancer Minimal Residual Disease Testing Market Size Forecast by Type (2025-2032)
 - 12.1.3 Global Forecasted Price of Cancer Minimal Residual Disease Testing by Type (2025-2032)
- 12.2 Global Cancer Minimal Residual Disease Testing Market Forecast by Application (2025-2032)
 - 12.2.1 Global Cancer Minimal Residual Disease Testing Sales (K Units) Forecast by Application
 - 12.2.2 Global Cancer Minimal Residual Disease Testing Market Size (M USD) Forecast by Application (2025-2032)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Cancer Minimal Residual Disease Testing Market Size Comparison by Region (M USD)

Table 5. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Manufacturers (2019-2024)

Table 6. Global Cancer Minimal Residual Disease Testing Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Cancer Minimal Residual Disease Testing Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Cancer Minimal Residual Disease Testing Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Minimal Residual Disease Testing as of 2022)

Table 10. Global Market Cancer Minimal Residual Disease Testing Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Cancer Minimal Residual Disease Testing Sales Sites and Area Served

Table 12. Manufacturers Cancer Minimal Residual Disease Testing Product Type

Table 13. Global Cancer Minimal Residual Disease Testing Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Cancer Minimal Residual Disease Testing

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Cancer Minimal Residual Disease Testing Market Challenges

Table 22. Global Cancer Minimal Residual Disease Testing Sales by Type (K Units)

Table 23. Global Cancer Minimal Residual Disease Testing Market Size by Type (M USD)

Table 24. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Type (2019-2024)

Table 25. Global Cancer Minimal Residual Disease Testing Sales Market Share by Type (2019-2024)

Table 26. Global Cancer Minimal Residual Disease Testing Market Size (M USD) by Type (2019-2024)

Table 27. Global Cancer Minimal Residual Disease Testing Market Size Share by Type (2019-2024)

Table 28. Global Cancer Minimal Residual Disease Testing Price (USD/Unit) by Type (2019-2024)

Table 29. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Application

Table 30. Global Cancer Minimal Residual Disease Testing Market Size by Application

Table 31. Global Cancer Minimal Residual Disease Testing Sales by Application (2019-2024) & (K Units)

Table 32. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application (2019-2024)

Table 33. Global Cancer Minimal Residual Disease Testing Sales by Application (2019-2024) & (M USD)

Table 34. Global Cancer Minimal Residual Disease Testing Market Share by Application (2019-2024)

Table 35. Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2024)

Table 36. Global Cancer Minimal Residual Disease Testing Sales by Region (2019-2024) & (K Units)

Table 37. Global Cancer Minimal Residual Disease Testing Sales Market Share by Region (2019-2024)

Table 38. North America Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)

Table 39. Europe Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)

Table 40. Asia Pacific Cancer Minimal Residual Disease Testing Sales by Region (2019-2024) & (K Units)

Table 41. South America Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)

Table 42. Middle East and Africa Cancer Minimal Residual Disease Testing Sales by Region (2019-2024) & (K Units)

Table 43. Global Cancer Minimal Residual Disease Testing Production (K Units) by Region (2019-2024)

Table 44. Global Cancer Minimal Residual Disease Testing Revenue (US\$ Million) by Region (2019-2024)

Table 45. Global Cancer Minimal Residual Disease Testing Revenue Market Share by Region (2019-2024)

Table 46. Global Cancer Minimal Residual Disease Testing Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 47. North America Cancer Minimal Residual Disease Testing Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 48. Europe Cancer Minimal Residual Disease Testing Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 49. Japan Cancer Minimal Residual Disease Testing Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 50. China Cancer Minimal Residual Disease Testing Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 51. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Basic Information

Table 52. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Overview

Table 53. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 54. Adaptive Biotechnologies Corporation Business Overview

Table 55. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing SWOT Analysis

Table 56. Adaptive Biotechnologies Corporation Recent Developments

Table 57. ArcherDX Cancer Minimal Residual Disease Testing Basic Information

Table 58. ArcherDX Cancer Minimal Residual Disease Testing Product Overview

Table 59. ArcherDX Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 60. ArcherDX Business Overview

Table 61. ArcherDX Cancer Minimal Residual Disease Testing SWOT Analysis

Table 62. ArcherDX Recent Developments

Table 63. Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Basic Information

Table 64. Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Overview

Table 65. Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 66. Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing SWOT Analysis

Table 67. Inc. (Invitae Corporation) Business Overview

- Table 68. Inc. (Invitae Corporation) Recent Developments
- Table 69. Asuragen Cancer Minimal Residual Disease Testing Basic Information
- Table 70. Asuragen Cancer Minimal Residual Disease Testing Product Overview
- Table 71. Asuragen Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 72. Asuragen Business Overview
- Table 73. Asuragen Recent Developments
- Table 74. Arup Laboratories Cancer Minimal Residual Disease Testing Basic Information
- Table 75. Arup Laboratories Cancer Minimal Residual Disease Testing Product Overview
- Table 76. Arup Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 77. Arup Laboratories Business Overview
- Table 78. Arup Laboratories Recent Developments
- Table 79. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Basic Information
- Table 80. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Overview
- Table 81. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 82. Bio-Rad Laboratories Business Overview
- Table 83. Bio-Rad Laboratories Recent Developments
- Table 84. Cergentis B.V. Cancer Minimal Residual Disease Testing Basic Information
- Table 85. Cergentis B.V. Cancer Minimal Residual Disease Testing Product Overview
- Table 86. Cergentis B.V. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 87. Cergentis B.V. Business Overview
- Table 88. Cergentis B.V. Recent Developments
- Table 89. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Basic Information
- Table 90. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Overview
- Table 91. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 92. F. Hoffmann- La Roche Ltd Business Overview
- Table 93. F. Hoffmann- La Roche Ltd Recent Developments
- Table 94. Guardant Health Cancer Minimal Residual Disease Testing Basic Information
- Table 95. Guardant Health Cancer Minimal Residual Disease Testing Product Overview

Table 96. Guardant Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 97. Guardant Health Business Overview

Table 98. Guardant Health Recent Developments

Table 99. ICON plc Cancer Minimal Residual Disease Testing Basic Information

Table 100. ICON plc Cancer Minimal Residual Disease Testing Product Overview

Table 101. ICON plc Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 102. ICON plc Business Overview

Table 103. ICON plc Recent Developments

Table 104. Invivoscribe Cancer Minimal Residual Disease Testing Basic Information

Table 105. Invivoscribe Cancer Minimal Residual Disease Testing Product Overview

Table 106. Invivoscribe Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 107. Invivoscribe Business Overview

Table 108. Invivoscribe Recent Developments

Table 109. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Basic Information

Table 110. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Overview

Table 111. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 112. Laboratory Corporation of America Holdings Business Overview

Table 113. Laboratory Corporation of America Holdings Recent Developments

Table 114. Mission Bio Cancer Minimal Residual Disease Testing Basic Information

Table 115. Mission Bio Cancer Minimal Residual Disease Testing Product Overview

Table 116. Mission Bio Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 117. Mission Bio Business Overview

Table 118. Mission Bio Recent Developments

Table 119. Natera Cancer Minimal Residual Disease Testing Basic Information

Table 120. Natera Cancer Minimal Residual Disease Testing Product Overview

Table 121. Natera Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 122. Natera Business Overview

Table 123. Natera Recent Developments

Table 124. Inc. Cancer Minimal Residual Disease Testing Basic Information

Table 125. Inc. Cancer Minimal Residual Disease Testing Product Overview

- Table 126. Inc. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 127. Inc. Business Overview
- Table 128. Inc. Recent Developments
- Table 129. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Basic Information
- Table 130. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Overview
- Table 131. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 132. NeoGenomics Laboratories Business Overview
- Table 133. NeoGenomics Laboratories Recent Developments
- Table 134. Opko Health Cancer Minimal Residual Disease Testing Basic Information
- Table 135. Opko Health Cancer Minimal Residual Disease Testing Product Overview
- Table 136. Opko Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 137. Opko Health Business Overview
- Table 138. Opko Health Recent Developments
- Table 139. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Basic Information
- Table 140. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Overview
- Table 141. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 142. Quest Diagnostics Incorporated Business Overview
- Table 143. Quest Diagnostics Incorporated Recent Developments
- Table 144. Sysmex Corporation Cancer Minimal Residual Disease Testing Basic Information
- Table 145. Sysmex Corporation Cancer Minimal Residual Disease Testing Product Overview
- Table 146. Sysmex Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 147. Sysmex Corporation Business Overview
- Table 148. Sysmex Corporation Recent Developments
- Table 149. Genetron Health Cancer Minimal Residual Disease Testing Basic Information
- Table 150. Genetron Health Cancer Minimal Residual Disease Testing Product Overview
- Table 151. Genetron Health Cancer Minimal Residual Disease Testing Sales (K Units),

Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 152. Genetron Health Business Overview

Table 153. Genetron Health Recent Developments

Table 154. Global Cancer Minimal Residual Disease Testing Sales Forecast by Region (2025-2032) & (K Units)

Table 155. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Region (2025-2032) & (M USD)

Table 156. North America Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2032) & (K Units)

Table 157. North America Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2032) & (M USD)

Table 158. Europe Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2032) & (K Units)

Table 159. Europe Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2032) & (M USD)

Table 160. Asia Pacific Cancer Minimal Residual Disease Testing Sales Forecast by Region (2025-2032) & (K Units)

Table 161. Asia Pacific Cancer Minimal Residual Disease Testing Market Size Forecast by Region (2025-2032) & (M USD)

Table 162. South America Cancer Minimal Residual Disease Testing Sales Forecast by Country (2025-2032) & (K Units)

Table 163. South America Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2032) & (M USD)

Table 164. Middle East and Africa Cancer Minimal Residual Disease Testing Consumption Forecast by Country (2025-2032) & (Units)

Table 165. Middle East and Africa Cancer Minimal Residual Disease Testing Market Size Forecast by Country (2025-2032) & (M USD)

Table 166. Global Cancer Minimal Residual Disease Testing Sales Forecast by Type (2025-2032) & (K Units)

Table 167. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Type (2025-2032) & (M USD)

Table 168. Global Cancer Minimal Residual Disease Testing Price Forecast by Type (2025-2032) & (USD/Unit)

Table 169. Global Cancer Minimal Residual Disease Testing Sales (K Units) Forecast by Application (2025-2032)

Table 170. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Application (2025-2032) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Cancer Minimal Residual Disease Testing

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Cancer Minimal Residual Disease Testing Market Size (M USD), 2019-2032

Figure 5. Global Cancer Minimal Residual Disease Testing Market Size (M USD) (2019-2032)

Figure 6. Global Cancer Minimal Residual Disease Testing Sales (K Units) & (2019-2032)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Cancer Minimal Residual Disease Testing Market Size by Country (M USD)

Figure 11. Cancer Minimal Residual Disease Testing Sales Share by Manufacturers in 2023

Figure 12. Global Cancer Minimal Residual Disease Testing Revenue Share by Manufacturers in 2023

Figure 13. Cancer Minimal Residual Disease Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Cancer Minimal Residual Disease Testing Average Price (USD/Unit) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Cancer Minimal Residual Disease Testing Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Cancer Minimal Residual Disease Testing Market Share by Type

Figure 18. Sales Market Share of Cancer Minimal Residual Disease Testing by Type (2019-2024)

Figure 19. Sales Market Share of Cancer Minimal Residual Disease Testing by Type in 2023

Figure 20. Market Size Share of Cancer Minimal Residual Disease Testing by Type (2019-2024)

Figure 21. Market Size Market Share of Cancer Minimal Residual Disease Testing by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Cancer Minimal Residual Disease Testing Market Share by

Application

Figure 24. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application (2019-2024)

Figure 25. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application in 2023

Figure 26. Global Cancer Minimal Residual Disease Testing Market Share by Application (2019-2024)

Figure 27. Global Cancer Minimal Residual Disease Testing Market Share by Application in 2023

Figure 28. Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2024)

Figure 29. Global Cancer Minimal Residual Disease Testing Sales Market Share by Region (2019-2024)

Figure 30. North America Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023

Figure 32. U.S. Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Cancer Minimal Residual Disease Testing Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Cancer Minimal Residual Disease Testing Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023

Figure 37. Germany Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Cancer Minimal Residual Disease Testing Sales Market Share by Region in 2023

Figure 44. China Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)

Figure 50. South America Cancer Minimal Residual Disease Testing Sales Market Share by Country in 2023

Figure 51. Brazil Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Cancer Minimal Residual Disease Testing Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Cancer Minimal Residual Disease Testing Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Cancer Minimal Residual Disease Testing Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Cancer Minimal Residual Disease Testing Production Market Share by Region (2019-2024)

Figure 62. North America Cancer Minimal Residual Disease Testing Production (K

Units) Growth Rate (2019-2024)

Figure 63. Europe Cancer Minimal Residual Disease Testing Production (K Units) Growth Rate (2019-2024)

Figure 64. Japan Cancer Minimal Residual Disease Testing Production (K Units) Growth Rate (2019-2024)

Figure 65. China Cancer Minimal Residual Disease Testing Production (K Units) Growth Rate (2019-2024)

Figure 66. Global Cancer Minimal Residual Disease Testing Sales Forecast by Volume (2019-2032) & (K Units)

Figure 67. Global Cancer Minimal Residual Disease Testing Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Cancer Minimal Residual Disease Testing Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Cancer Minimal Residual Disease Testing Market Share Forecast by Type (2025-2032)

Figure 70. Global Cancer Minimal Residual Disease Testing Sales Forecast by Application (2025-2032)

Figure 71. Global Cancer Minimal Residual Disease Testing Market Share Forecast by Application (2025-2032)

I would like to order

Product name: Global Cancer Minimal Residual Disease Testing Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/G99B1D8E24D1EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G99B1D8E24D1EN.html>